Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?

Hepatology

Volumn 54, Issue 4, 2011, Pages 1454-1462

  Guha, Indra Neil ^a   Myers, Robert P ^b   Patel, Keyur ^c   Talwalkar, Jayant A ^d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERFERON;

CLINICAL PRACTICE; CLINICAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIGESTIVE TRACT PARAMETERS; DOPPLER ECHOGRAPHY; EXTERNAL VALIDITY; GOLD STANDARD; HEPATIC VEIN TRANSIT TIME; HEPATITIS C; HISTOLOGY; HUMAN; INTERVENTION STUDY; LIVER BIOPSY; LIVER FIBROSIS; METHODOLOGY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; FEMALE; GREAT BRITAIN; HUMANS; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 81155162421     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24515     Document Type: Review

References (50)

1. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008; 12: 883-900.
2. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681.
3. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 462-474.
4. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 1650-1660.
5. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. HEPATOLOGY 2007; 46: 912-921.
6. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-2600.
7. Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008; 9: 43-51.
8. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin Chem 2003; 49: 7-18.
9. Bossuyt PM. STARD statement: still room for improvement in the reporting of diagnostic accuracy studies. Radiology 2008; 248: 713-714.
10. Wilczynski NL. Quality of reporting of diagnostic accuracy studies: no change since STARD statement publication-before-and-after study. Radiology 2008; 248: 817-823.
11. Smidt N, et al. Quality of reporting of diagnostic accuracy studies. Radiology 2005; 235: 347-353.
12. Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. HEPATOLOGY 2010; 51: 828-835.
13. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299: 926-930.
14. Goehring C, Perrier A, Morabia A. Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performance. Stat Med 2004; 23: 125-135.
15. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007; 53: 1615-1622.
16. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54: 1372-1378.
17. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974.
18. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. HEPATOLOGY 2009; 49: 1017-1044.
19. Perrillo RP. The role of liver biopsy in hepatitis C. HEPATOLOGY 1997; 26: 57S-61S.
20. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-961.
21. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci State 2002; 19: 1-46.
22. Ghany MG, trader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 1335-1374.
23. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
24. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
25. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313-1321.
26. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. HEPATOLOGY 2009; 49: 97-105.
27. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003; 38: 1449-1457.
28. Cholongitas E, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006; 125: 710-721.
29. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. HEPATOLOGY 2005; 41: 257-264.
30. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. HEPATOLOGY 2009; 50: 1738-1749.
31. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. HEPATOLOGY 2009; 50: 1294-1306.
32. McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, et al. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 2010; 138: 1365-1373 e1-2.
33. Gailhouste L, Le Grand Y, Odin C, Guyader D, Turlin B, Ezan F, et al. Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J Hepatol 2010; 52: 398-406.
34. Ghiassi-Nejad Z, Friedman SL. Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol 2008; 2: 803-816.
35. Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133.
36. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
37. Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-1220.
38. Friedrich-Rust M, Wunder K, Kreiner S, Sotoudeh F, Richter S, Bojunga J, et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604.
39. Muthupillai R, Ehman RL. Magnetic resonance elastography. Nat Med 1996; 2: 601-603.
40. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973.
41. Hines CD, Bley TA, Lindstrom MJ, Reeder SB. Repeatability of magnetic resonance elastography for quantification of hepatic stiffness. J Magn Reson Imaging 2010; 31: 725-731.
42. Talwalkar JA. Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology 2008; 135: 299-302.
43. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254: 47-66.
44. Solga SF, Horska A, Clark JM, Diehl AM. Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide. Liver Int 2005; 25: 490-500.
45. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. HEPATOLOGY 2010; 51: 1445-1449.
46. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138: 136-146.
47. Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-1251.
48. Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. HEPATOLOGY 2008; 48: 1549-1557.
49. Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147-158 e1.
50. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010; 59: 861-866.